[{“box”:0,”content”:”n[if 992 equals=”Open Access”]n
n
Open Access
nn
n
n[/if 992]n[if 2704 equals=”Yes”]n
nThis is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.n
n[/if 2704]n
n
n
nn
n
Prachi Rajesh Patil, Shweta Vinod Raul, Sunila A Patil,
n t
n
n[/foreach]
n
n[if 2099 not_equal=”Yes”]n
- [foreach 286] [if 1175 not_equal=””]n t
- Student, Student, Assistant Professor, Department of Pharmaceutical Quality Assurance, P.S.G.V.P Mandal’s College of Pharmacy, Untavad, Department of Pharmaceutical Quality Assurance, P.S.G.V.P Mandal’s College of Pharmacy, Untavad, Department of Pharmaceutical Quality Assurance, P.S.G.V.P Mandal’s College of Pharmacy, Untavad, Maharashtra, Maharashtra, Maharashtra, India, India, India
n[/if 1175][/foreach]
n[/if 2099][if 2099 equals=”Yes”][/if 2099]n
Abstract
n
n
nThis brief overview outlines the global techniques for figuring out the prevalence of geotaxis impurities (residual solvents and various inorganic and organic impurities) in medications. It is now necessary to reveal a pharmaceutical product’s purity and impurity profiles due to both national and international regulations. These elements are discussed, together with the kinds of impurities, their origins, their control, and regulatory issues, as well as the significance of pharmaceutical quality, efficacy, and safety. The availability of high-quality important pharmaceuticals is a must for the supply of any country’s healthcare system, as inferior medications have the potential to injure or even kill consumers. A medication’s safety and efficacy may be impacted by the presence of unwanted chemicals, even in very small concentrations. Unlike products in other industries, pharmaceuticals are dynamic, and both during production and after final consumption, their color, consistency, weight, and even chemical identity can change. As a result, pharmaceutical quality has long been a global concern and is currently gaining significant attention from regulatory bodies. Pharmaceutical product impurities are a major concern because of the potential harm they may do to medicine stability and shelf life in addition to the intrinsic toxicity of some contaminants. In pharmaceutical and drug products, impurities are harmful chemicals (natural, inorganic, and residual solvents) that can be introduced or created during formulation, aging, or retention with the active pharmaceutical ingredients (APIs). The most prevalent impurities in all APIs are organic ones, which, even with appropriate handling, are naturally incorporated during the multi-step synthesis process.nn
n
Keywords: Practical consideration in developing QA/QC system, Element of QA & QC, Inventory Agency, QA/QC Plans, QA procedure, Q. Assurance, Review process, Methodology.
n[if 424 equals=”Regular Issue”][This article belongs to Research & Reviews: A Journal of Drug Formulation, Development and Production ]
n
n
n
n
nPrachi Rajesh Patil, Shweta Vinod Raul, Sunila A Patil. [if 2584 equals=”][226 wpautop=0 striphtml=1][else]Quality Control and Assurance Practices in Modern Pharmaceutical Industry[/if 2584]. Research & Reviews: A Journal of Drug Formulation, Development and Production. 11/10/2025; 12(03):-.
n
nPrachi Rajesh Patil, Shweta Vinod Raul, Sunila A Patil. [if 2584 equals=”][226 striphtml=1][else]Quality Control and Assurance Practices in Modern Pharmaceutical Industry[/if 2584]. Research & Reviews: A Journal of Drug Formulation, Development and Production. 11/10/2025; 12(03):-. Available from: https://journals.stmjournals.com/rrjodfdp/article=11/10/2025/view=0
nn
n
n[if 992 not_equal=”Open Access”]n
n
n[/if 992]n
nn
n nnBrowse Figures
n
n
n[/if 379]
n
n
n
References n
n[if 1104 equals=””]n
- Intergovernmental Panel on Climate Change (IPCC) (1997). Revised 1996 IPCC Guidelines for National Greenhouse Gas Inventories: Volumes 1, 2 and 3. J.T. Houghton et al., IPCC/OECD/IEA, Paris, France.
- Handbook of International Auditing, Assurance, and Ethics Pronouncements, International Federation of Accountants, March 2008
- Rodionova, O. Y., Sokovikov, Y. V., & Pomerantsev, A. L. Quality control of packed raw materials in pharmaceutical industry. analytica chimica acta, 2009; 642(1): 222-227.
- Quality Assurance in Financial Auditing, A Handbook, IDI-ASOSAI, 2009
- Handbook on Quality Assurance in Performance Auditing, IDI-ASOSAI, 2011
- International Organization for Standardization (ISO) (1994). Air Quality, Determination of Performance Characteristics of Measurement Methods. ISO 9196:1994. ISO, Geneva, Switzerland
- Quality Assurance Handbook, IDI-AFROSAI-E, 2007
- Feigenbaum, Armand V (1956). “Total Quality Control”; Harvard Business Review. 34(6):93–101.
- https://www.firsttimequality.com/Blog/bid/235096-Essential-Elements-of-a-Construction-Quality-QA-QC-Plan-Framework#:text=An%20executive%20overview%20G%20your%20QA%20company%20does%20to%20manage%20quality&text=The%20HOW%20details%20should%20be%20included%20in%20your%20policies%20and%20procedures%20document
- EN ISO 9001: 2000 “Quality Management Systems – Requirements”, published December 2000
- Ezzelle, J., Rodriguez-Chavez, I. R., Darden, J. M., Stirewalt, M., Kunwar, N., Hitchcock, R., & D’souza M. P. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. Journal of pharmaceutical and biomedical analysis, 2008; 46(1): 18-29.
- Bakshi, M., & Singh, S. Development of validated stability-indicating assay methods critical review. Journal of pharmaceutical and biomedical analysis, 2002; 28(6): 1011- 1040
- How to set up QA Processes from Scratch https://www.browserstack.com/guide/setup-qa-process.
- Cockburn, I. M. The changing structure of the pharmaceutical industry. Health Affairs, 2004; 23(1): 10-22
- Carpenter, D. P. The political economy of FDA drug review: processing, politics, and lessons for policy. Health Affairs, 2004; 23(1): 52-63
- Kayser, O., & Warzecha, H. Pharmaceutical biotechnology: drug discovery and clinical applications. John Wiley & Sons 2012.
- Lund, W. The pharmaceutical codex: principles and practice of pharmaceutics (No. Ed. 12). Royal Pharmaceutical Society of Great Britain 1994.
- Henderson, R., Orsenigo, L., & Pisano, G. P. The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional, and organizational change. Sources of industrial leadership: studies of seven industries, 1999; 267-311
nn[/if 1104][if 1104 not_equal=””]n
- [foreach 1102]n t
- [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
n[/foreach]
n[/if 1104]
n
nn[if 1114 equals=”Yes”]n
n[/if 1114]
n
n

n
Research & Reviews: A Journal of Drug Formulation, Development and Production
n
n
n
n
nn
n
| Volume | 12 | |
| [if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] | 03 | |
| Received | 27/06/2025 | |
| Accepted | 31/07/2025 | |
| Published | 11/10/2025 | |
| Retracted | ||
| Publication Time | 106 Days |
n
n
nn
n
Login
PlumX Metrics
n
n
n[if 1746 equals=”Retracted”]n
[/if 1746]nnn
nnn”}]